Alzheimer's & Dementia®
THE JOURNAL OF THE ALZHEIMER'S ASSOCIATION

SHORT REPORT

Distinct spatial contributions of amyloid pathology and cerebral small vessel disease to hippocampal morphology

Kristiana Xhima[1] | Julie Ottoy[1] | Erin Gibson[1] | Katherine Zukotynski[1,2,3] |
Christopher Scott[1] | Ginelle J. Feliciano[1] | Sabrina Adamo[1] | Phillip H. Kuo[4] |
Michael J. Borrie[5] | Howard Chertkow[6] | Richard Frayne[7] | Robert Laforce Jr.[8] |
Michael D. Noseworthy[2,9] | Frank S. Prato[5] | Demetrios J. Sahlas[10] | Eric E. Smith[11] |
Vesna Sossi[12] | Alexander Thiel[13] | Jean-Paul Soucy[14] | Jean-Claude Tardif[15] |
Maged Goubran[1,16,17] | Sandra E. Black[1,18] | Joel Ramirez[1] | for the Medical Imaging
Trials Network of Canada (MITNEC)

[1]Dr. Sandra E. Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada

[2]Departments of Medicine and Radiology, McMaster University, Hamilton, Ontario, Canada

[3]Department of Medical Imaging, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada

[4]Departments of Medical Imaging, Medicine, Biomedical Engineering, University of Arizona, Tucson, Arizona, USA

[5]Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada

[6]Rotman Research Institute, Baycrest Health Sciences, Toronto, Ontario, Canada

[7]Departments of Radiology and Clinical Neuroscience, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada

[8]Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, Université Laval, Quebec City, Quebec, Canada

[9]Department of Electrical and Computer Engineering, McMaster University, Hamilton, Ontario, Canada

[10]Department of Medicine, McMaster University, Hamilton, Ontario, Canada

[11]Department of Clinical Neurosciences and Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada

[12]Physics and Astronomy Department and DM Center for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada

[13]Department of Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada

[14]Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada

[15]Montreal Heart Institute, Université de Montréal, Montreal, Quebec, Canada

[16]Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

[17]Physical Sciences Platform, Sunnybrook Research Institute, University of Toronto, Toronto, Ontario, Canada

[18]Division of Neurology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada

Correspondence
Kristiana Xhima and Joel Ramirez, Dr. Sandra E. Black Centre for Brain Resilience and Recovery, LC Campbell Cognitive Neurology, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, University of Toronto, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada.

Abstract
INTRODUCTION: Cerebral small vessel disease (SVD) and amyloid beta (Aβ) pathology frequently co-exist. The impact of concurrent pathology on the pattern of hippocampal atrophy, a key substrate of memory impacted early and extensively in dementia, remains poorly understood.

Email: kristiana.xhima@mail.utoronto.ca and
joel.ramirez1@sunnybrook.ca

Sandra E. Black and Joel Ramirez are co-senior
authors.

METHODS: In a unique cohort of mixed Alzheimer's disease and moderate–severe SVD, we examined whether total and regional neuroimaging measures of SVD, white matter hyperintensities (WMH), and Aβ, as assessed by ^{18}F-AV45 positron emission tomography, exert additive or synergistic effects on hippocampal volume and shape.

RESULTS: Frontal WMH, occipital WMH, and Aβ were independently associated with smaller hippocampal volume. Frontal WMH had a spatially distinct impact on hippocampal shape relative to Aβ. In contrast, hippocampal shape alterations associated with occipital WMH spatially overlapped with Aβ-vulnerable subregions.

DISCUSSION: Hippocampal degeneration is differentially sensitive to SVD and Aβ pathology. The pattern of hippocampal atrophy could serve as a disease-specific biomarker, and thus guide clinical diagnosis and individualized treatment strategies for mixed dementia.

KEYWORDS
Alzheimer's disease, amyloid, biomarker, cerebral small vessel disease, hippocampal shape, hippocampal volume, Medical Imaging Trials Network of Canada C6 Project, mixed dementia, neurodegeneration, vascular, white matter hyperintensities

1 | BACKGROUND

Alzheimer's disease (AD) and cerebral small vessel disease (SVD) are the most common causes of dementia. Mixed pathologies co-occur in the vast majority of patients and increase the risk of dementia.[1] AD is characterized by the deposition of amyloid beta (Aβ) plaques, neurofibrillary tau tangles, and neurodegeneration.[2] SVD refers to neuropathological processes affecting small penetrating vessels, commonly visualized on magnetic resonance imaging (MRI) as white matter hyperintensities (WMH), enlarged perivascular spaces (PVS), lacunes, and microbleeds.[3] Interactions between both disease processes in clinical populations highlight the need for a better understanding of the relative contributions of AD and SVD to neurodegeneration and cognitive decline in individual patients.

An important point of convergence for both AD and SVD is hippocampal atrophy, a key substrate for cognitive impairment in dementia, and an important biomarker for clinical diagnosis, prognosis, and therapeutic trials for AD.[2] Hippocampal degeneration has been associated with both AD and SVD, however, studies assessing the dynamic interplay between these pathologies on hippocampal structure are scarce and their interactive effects on hippocampal morphology remain poorly understood.[2,4] Specifically, it remains unresolved whether SVD pathology influences hippocampal atrophy independently, through AD-related pathways, or both. The relationship between WMH and hippocampal volume in mild cognitive impairment (MCI) and AD patients is inconclusive, showing associations in some studies that relied on clinically defined MCI[5–9] or AD,[8–11] but rarely evaluated in the presence of Aβ or tau biomarkers.[8,9] Additionally, little is known about the effect of regional SVD on hippocampal structure, which has not yet been investigated in the context of AD-

related biomarkers.[5,6,12] Converging evidence supports a link between the spatial distribution of WMH and distinct pathophysiological mechanisms in AD, with anterior WMH mostly linked to deficits in regional perfusion, and posterior WMH more specifically associated with AD, highlighting the utility of a regionalized approach to reveal how SVD and AD pathologies may coexist and interact.[13,14] Taken together, further understanding the pattern of hippocampal atrophy in mixed dementia with biomarker-based tools has strong potential to disentangle the independent and/or synergistic contributions of AD pathology and vascular injury to downstream hippocampal degeneration and cognitive decline, thereby improving our understanding of the clinical impact and effective therapeutic strategies for mixed dementia.

A critical gap in our ability to interpret the interrelationships between AD and SVD pathologies remains the significant underrepresentation of the mixed dementia phenotype in clinical studies. Despite the high prevalence of mixed etiologies clinically, individuals with moderate–extensive co-occurring vascular and Aβ burden—the population most likely to reveal interactive relationships between concomitant disease pathologies and most reflective of real-world clinical populations—are often excluded from clinical studies. Previous study cohorts have been limited to investigation of either pure AD in the absence of significant vascular disease history, or pure vascular dementia without Aβ deposition or unknown Aβ status, potentially resulting in misdiagnosis between vascular and mixed dementia. In this study, we evaluate the interactive effects of overlapping AD and SVD in the Medical Imaging Trials Network of Canada Project C6 Project (MITNEC-C6), a unique multicenter prospective observational study designed to specifically recruit cognitively impaired individuals with moderate–severe SVD in addition to Aβ positron emission tomography (PET) positivity (NCT02330510).

Other important gaps include the study of interactive effects on hippocampal structure using hippocampal volumetry tools not validated in patients with extensive atrophy and cerebrovascular lesions.[15] This is particularly relevant as mixed dementia can involve a substantial degree of hippocampal volume loss, which is difficult to accurately segment. Additionally, reliable volumetric measurements enable more sensitive hippocampal shape analyses to further infer regional patterns of hippocampal atrophy and their potential connections to distinct pathological mechanisms.[16]

To address these limitations, the objective of the present study was to gain deeper insight into the links between Aβ burden, WMH, and hippocampal degeneration, in a unique cohort of cognitively impaired adults with moderate–severe SVD with and without Aβ PET positivity, using a novel, state-of-the-art hippocampal segmentation tool to analyze alterations of hippocampal structure. Specifically, we hypothesized that among individuals with mixed dementia, (1) Aβ and SVD pathology independently contribute to hippocampal atrophy and (2) the spatial distribution of WMH differentially influences the pattern of hippocampal atrophy.

2 | METHODS

2.1 | Participants

Sixty-nine participants were recruited from stroke prevention clinics (clinical diagnosis of transient ischemic attack or subcortical lacunar infarct ≤ 1.5 cm) and memory clinics (clinical diagnosis of MCI or early AD), as part of the MITNEC-C6, a multicenter prospective observational study (NCT02330510). Inclusion criteria included moderate-to-severe SVD (i.e., periventricular WMH with Fazekas score ≥ 2, with Fazekas 2 subjects included only if bilateral anterior or posterior periventricular WMH caps extended ≥ 10 mm from the ventricle or at least midway into the surrounding white matter), ≥ 60 years of age, expected survival > 2 years, Mini-Mental State Examination (MMSE) ≥ 20, > 8 years of education, and sufficient fluency in English or French for cognitive assessment. Exclusion criteria included cortical or non-lacunar infarct, persisting hemiparesis after a motor stroke, leg strength < 4/5 on the Medical Research Council scale, cerebellar ataxia, contraindications to 3T MRI, major psychiatric diagnosis within the last 5 years, history of substance abuse in the preceding 2 years, neurological diagnosis other than AD (e.g., Parkinson's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, significant head trauma), pain or sleep disorder that interferes with participation, claustrophobia, head or neck radiation therapy or involvement in research study with radiation, and/or an inability or unwillingness to adhere to protocol requirements. All participants underwent standardized neuroimaging and cognitive testing described elsewhere.[17] All participants provided written informed consent. Research was ethically conducted and approved by each participating institutional ethics board.

RESEARCH IN CONTEXT

1. **Systematic review**: The authors reviewed PubMed for literature concerning the impact of Alzheimer's disease (AD) and small vessel disease (SVD) pathologies on hippocampal degeneration. Although the link between amyloid beta (Aβ) and low white matter hyperintensity (WMH) load with reduced hippocampal volume has been studied, patients with significantly overlapping mixed AD/SVD pathology—representing the vast majority of patients clinically—have been largely excluded from clinical trials. Interactive effects between these co-pathologies on the spatial pattern of hippocampal atrophy remain unexplored.

2. **Interpretation**: In a unique cohort of mixed AD and moderate–extensive SVD, frontal and occipital WMH, and Aβ positron emission tomography positivity were independently associated with smaller hippocampal volume. Frontal WMH uniquely affected hippocampal shape whereas occipital WMH spatially overlapped with Aβ-vulnerable subregions, revealing differential sensitivity of the hippocampus to SVD and Aβ pathology.

3. **Future directions**: Future validation and longitudinal studies in mixed AD/SVD cohorts will advance the utility of hippocampal morphology as a disease-specific biomarker for improving diagnosis and personalized treatments for mixed dementia.

2.2 | Neuroimaging

Each participant underwent standardized 3T MRI (T1, PD-T2, FLAIR) and ^{18}F-AV45 amyloid PET.[17] WMH, lacunes, and PVS volumes were quantified using automated segmentation and regional parcellation tools on structural MRI.[18,19] WMH volumes were extracted for frontal, temporal, parietal, occipital, and basal ganglia/thalamic regions. To mitigate skewness, all WMH volumes were log transformed. Hippocampal volumes were quantified using HippMapp3r, a deep learning segmentation algorithm that is robust to extensive atrophy, cerebrovascular lesions, and multisite imaging.[15] Hippocampal shape analysis was performed using the SPHARM-PDM pipeline.[16] Briefly, HippMapp3r segmentation serves as input from which a mesh surface and spherical parameterization were extracted for each participant's hippocampi. Individual surfaces were registered to a surface template (averaged from all participants) creating point correspondences between hippocampi. Point-wise hippocampal deformations relative to the template were successfully extracted in all participants. To account for interindividual variation in head size, all volumes were normalized to supratentorial total intracranial volume (ST-TIV), calculated as the sum of gray matter volume, white matter volume, and cerebrospinal fluid (CSF) volume in each subject. Two dual-certified nuclear medicine

physicians/radiologists (KZ, PHK), blinded to each other's assessments, clinically interpreted ^{18}F-AV45 amyloid PET scans as Aβ positive or Aβ negative.

2.3 | Statistical analyses

Statistical analyses were performed using SPSS (version 24.0). Chi-squared tests for categorical variables, two-tailed t tests for normally distributed continuous variables, and non-parametric Wilcoxon rank-sum test for non-normally distributed continuous variables were performed to compare demographics, neuroimaging, and clinical variables between Aβ-positive and Aβ-negative participants. Linear regression models were used to investigate whether Aβ status and WMH volume independently predicted hippocampal volume, adjusted for age, sex, and education. An interaction term between Aβ status and WMH volume was included to determine whether these pathologies interacted to disproportionally impact hippocampal volume. Heteroscedasticity and multiple comparisons were controlled for by bias-corrected bootstrapping (5000 replications and 99% confidence intervals). SPHARM-PDM landmarks were used to compare point-wise hippocampal surface differences between groups, adjusted for head size, age, sex, and education using a multivariate varying coefficient model using Slicer-SALT software. Outliers were defined using the Tukey method. No outliers were detected across all global and regional neuroimaging metrics. Cook's distance was calculated for linear regression analyses with no observations exceeding the influence threshold across analyses.

3 | RESULTS

Participant characteristics are summarized in Table 1. Twenty-seven of 69 individuals (39%) were Aβ positive. Aβ positive and Aβ negative individuals were comparable in terms of sex, education, and vascular risk factors (hypertension, diabetes, hyperlipidemia, smoking). Age was slightly higher in the Aβ positive group (79.69 $\pm$ 6.84 years vs. 74.22 $\pm$ 8.67 years, $P = 0.02$). MMSE and Montreal Cognitive Assessment (MoCA) scores were marginally lower in the Aβ positive group, consistent with mild–moderate cognitive impairment (MMSE: 26.13 $\pm$ 2.92 vs. 27.25 $\pm$ 2.42, $P = 0.02$; MoCA: 20.07 $\pm$ 4.17 vs. 22.73 $\pm$ 5.35, $P = 0.02$). Compared to Aβ negative patients, Aβ positive patients did not differ in terms of SVD neuroimaging measures, but showed smaller hippocampal volumes (5.12 $\pm$ 0.94 cm^3 vs. 5.83 $\pm$ 0.96 cm^3, $P = 0.003$), driven by atrophy in both the left (2.54 $\pm$ 0.43 cm^3 vs. 2.85 $\pm$ 0.47 cm^3, $P = 0.02$) and right (2.58 $\pm$ 0.55 cm^3 vs. 2.99 $\pm$ 0.53 cm^3, $P = 0.01$) hippocampi. Group differences in hippocampal volume remained significant in analyses adjusted for age, sex, and education.

Next, we investigated the additive and interactive effects of Aβ status and WMH volume on hippocampal volume. Positive Aβ status was associated with smaller hippocampal volume, adjusted for age, sex, education, and total WMH volume (Table S1 in supporting information; $\beta = -0.20$, $P = 0.04$). In contrast to total WMH volume (Table S1; $\beta = -0.06$, $P = 0.76$), greater WMH volume in the frontal and occipital regions predicted lower hippocampal volume independent of Aβ deposition, age, sex, and education (Table 2; frontal WMH: $\beta = -0.26$, $P = 0.03$; occipital WMH: $\beta = -0.35$, $P = 0.01$). We observed no interaction between Aβ positivity and regional WMH in terms of their impact on hippocampal volume (Table 2), supporting the notion that global Aβ burden and regional WMH volume act in an additive rather than synergistic way to affect hippocampal volume.

To delineate whether subregions of the hippocampus are differentially affected by Aβ and regional WMH, we performed hippocampal morphometry analysis (Figure 1). Aβ positivity was linked to inward deformation of the right superolateral head, lateral body, and tail, as well as left medial body and bilateral inferomedial head—hippocampal subregions that likely correspond to atrophy in the CA1 and subiculum (Figure 1A). Frontal WMH burden was linked to inward deformation of the left superolateral and inferomedial hippocampal surface, with a similar pattern to a lesser extent on the right hippocampus, largely corresponding to CA1 atrophy that is spatially distinct from hippocampal subregions affected in Aβ positive subjects (Figure 1B). Parietal WMH were associated with outward deformations in the right superolateral head, right tail, and left lateral body (Figure 1C), implicating the CA2/CA3 and CA4/DG hippocampal subfields. Temporal WMH burden was associated with outward displacements in the bilateral hippocampal heads (Figure 1D), corresponding to CA1 and subiculum, while occipital WMH burden had similar and overlapping subregional morphological alterations (inward deformations) with that of Aβ positivity (Figure 1E). Finally, basal ganglia/thalamic lesion load was linked to outward deformations of the left hippocampal tail and right lateral hippocampal surface (Figure 1F), largely corresponding to CA1 and subiculum.

4 | DISCUSSION

Analysis of hippocampal morphology revealed novel spatial associations between global Aβ burden and SVD pathology driving hippocampal neurodegeneration in dementia. The pattern of hippocampal atrophy is differentially sensitive to the effects of Aβ and regional SVD. Relative to Aβ-susceptible subregions, the pattern of degeneration was spatially unique for frontal WMH and spatially similar for occipital WMH, implicating distinct pathological mechanisms driving degeneration. Leveraging these distinct contributions, hippocampal shape may have the potential to serve as a disease-specific biomarker that captures the relative impact of commonly co-occurring AD and SVD pathologies on neurodegeneration and thus inform clinical diagnosis and individualized treatment strategies for mixed dementia.

These findings are consistent with previous studies demonstrating the independent but additive effects of Aβ pathology and concurrent total WMH burden on hippocampal volume in cognitively unimpaired older adults and patients with MCI or early AD.[8,9,20–22] However, to our knowledge, the regional specificity of WMH on the pattern of hippocampal degeneration has not been previously investigated. Previous studies observed a posterior predominance of WMH in the context

FIGURE 1 Hippocampal shape alterations associated with Aβ status and regional WMH volumes in MITNEC-C6 subjects. Regional hippocampal surface deformities associated with (A) Aβ positivity, and regional WMH load, localized to the (B) frontal lobe, (C) parietal lobe, (D) temporal lobe, (E) occipital lobe, and (F) basal ganglia/thalamus. The left side of each panel shows the relative displacement map (blue = outward displacement, red = inward displacement) associated with each disease process and the right side of each panel indicates the P-value map related to each hippocampal surface. Aβ, amyloid beta; MITNEC-C6, Medical Imaging Trials Network of Canada Project C6; WMH, white matter hyperintensities.

TABLE 1 Demographics, clinical characteristics, and neuroimaging measures in study participants.

Variables	Aβ positive (n = 27)	Aβ negative (n = 42)	P-value
Demographics			
Age, years, mean (SD)	79.69 (6.84)	74.22 (8.67)	0.02*[a]
Sex, female, n (%)	13 (48.1%)	19 (43.2%)	0.68[b]
Education, years	15.85 (3.79)	14.48 (3.37)	0.12[a]
Vascular risk factors			
Hypertension, n (%)	21 (77.8%)	32 (72.7%)	0.64[b]
Diabetes mellitus, n (%)	4 (14.8%)	3 (6.8%)	0.27[b]
Hyperlipidemia, n (%)	21 (77.8%)	26 (59.1%)	0.11[b]
Smoking, n (%)	13 (48.1%)	17 (40.4%)	0.53[b]
Cardiovascular disease, n (%)	11 (40.7%)	16 (38.1%)	0.83[b]
Previous TIA, n (%)	8 (29.6%)	11 (25.0%)	0.67[b]
Previous stroke, n (%)	3 (11.1%)	13 (29.5%)	0.07[b]
Neuroimaging			
ST-TIV, cm^3	1239 (111.44)	1196.90 (320.90)	0.51[c]
BPF, %	69.98 (3.59)	72.03 (5.41)	0.07[a]
WMH volume, cm^3	36.87 (23.81)	38.07 (21.14)	0.82[c]
Frontal	13.38 (9.97)	14.75 (9.42)	0.49[c]
Parietal	16.21 (12.61)	16.02 (9.93)	0.80[c]
Temporal	4.36 (3.49)	4.29 (3.06)	0.67[c]
Occipital	2.79 (2.16)	2.61 (2.06)	0.69[c]
Basal ganglia/thalamic	0.52 (0.75)	0.65 (1.03)	0.89[c]
Lacunes, mm^3	860.81 (593.44)	890.18 (1125.12)	0.93[c]
PVS, mm^3	112.93 (104.44)	148.93 (120.39)	0.49[c]
Hippocampal volume, cm^3	5.12 (0.94)	5.83 (0.96)	0.003*[a]
Left	2.54 (0.43)	2.85 (0.47)	0.02*[a]
Right	2.58 (0.55)	2.99 (0.53)	0.01*[a]
Cognition			
MMSE, /30	26.13 (2.92)	27.25 (2.42)	0.02*[a]
MoCA, /30	20.07 (4.17)	22.73 (5.35)	0.02*[a]

Note: Raw neuroimaging volumetrics are reported in the table, but statistical analyses were conducted with ST-TIV corrected values. *P*-values comparing Aβ-positive versus Aβ-negative subjects. Values represent mean (standard deviation) or count (percentage).
Abbreviations: Aβ, amyloid beta; BPF, brain parenchymal fraction; MMSE, Mini-Mental State Examination; MoCA, Montreal Cognitive Assessment; PVS, perivascular spaces; SD, standard deviation; ST-TIV, supratentorial total intracranial volume; TIA, transient ischemic attack; WMH, white matter hyperintensities.
[a]Student *t* test.
[b]Chi-squared test.
[c]Wilcoxon rank-sum test.
*P-value < 0.05.

of sporadic and familial AD, implicating Aβ-mediated white matter damage in posterior brain regions.[13,14,23,24] Consistent with this distribution, we show that hippocampal shape alterations associated with occipital WMH spatially overlap with Aβ-vulnerable subregions of the hippocampus. The relative distribution of WMH shifts posteriorly as WMH burden increases, supporting the observed occipital association over other posterior regions in this higher vascular burden cohort.[25,26] Cerebral amyloid angiopathy (CAA) follows a similar posteroanterior gradient in AD and correlates to hippocampal atrophy.[25]

Mechanistically, CAA-related ischemic damage may explain the direct convergence of occipital WMH and Aβ pathology on hippocampal integrity. Venous collagenosis may also be implicated, impairing regional perivascular and interstitial fluid flow from white matter and thus Aβ clearance.[27,28] Other possible underlying pathological processes include localized Wallerian degeneration, oxidative stress, inflammation, and oligodendrocyte damage.[3] Together, our findings reveal the convergence of occipital SVD and global Aβ on downstream hippocampal degeneration.

TABLE 2 Association between Aβ status and WMH volume with hippocampal volume.

Predictor	β coefficient between predictor and HV[a]	P-value[a]	Interaction term Aβ status × WMH volume[b]	P-value[b]
Age, years	−0.46	<0.0001*	–	–
Sex, female, n	0.39	<0.0001*	–	–
Education, years	−0.19	0.03*	–	–
Aβ positive, n	−0.20	0.03*	–	–
Frontal WMH, cm³	−0.26	0.03*	−0.11	0.61
Parietal WMH, cm³	0.30	0.07	−0.02	0.82
Temporal WMH, cm³	0.25	0.18	0.23	0.16
Occipital WMH, cm³	−0.35	0.01*	0.05	0.77
Basal ganglia/thalamic WMH, cm³	0.23	0.31	0.07	0.81

Abbreviations: Aβ, amyloid beta; HV, hippocampal volume; WMH, white matter hyperintensities.

[a]Multivariable linear regression model with hippocampal volume as the outcome and age, sex, education, Aβ status, regional WMH as predictors.

[b]Interaction terms added to the linear regression model separately.

*P-value < 0.05, bias-corrected bootstrapping with 5000 replications and 99% confidence interval.

In contrast, frontal WMH impact spatially distinct areas within the hippocampus relative to Aβ. Frontal white matter is preferentially susceptible to vascular injury, consistent with an anterior dominant WMH distribution in patients with sporadic and familial SVD.[3] Mechanistically, WMH localized to the frontal horns of the lateral ventricles are particularly susceptible to chronic hypoperfusion, oxidative stress and white matter injury, given the significant distance between penetrating arterioles and draining venules toward the ventricles.[29] Functional disconnection between frontal association areas subserving the hippocampus due to ischemic damage could lead to hippocampal atrophy and axonal degeneration. Our observations provide evidence that concurrent frontal SVD and Aβ potentially represent independent pathways to hippocampal atrophy. Indeed, frontal lobe WMH burden associated with hippocampal atrophy, regardless of dementia status.[30] Parietal, temporal, and basal ganglia/thalamic WMH load were associated with outward deformation of the hippocampal surface, and may implicate inflammatory or compensatory mechanisms in affected hippocampal subfields.[31,32]

Several unique aspects of this study strengthen our results related to the complex interactions between concomitant Aβ and SVD on hippocampal morphology. First, the MITNEC-C6 cohort includes participants with significant vascular and Aβ co-pathology, who are often explicitly excluded from AD studies and clinical trials despite the high prevalence of mixed pathology clinically. Second, we conducted hippocampal segmentation using a novel machine learning algorithm, HippMapp3r, shown to be robust in patients with extensive atrophy and cerebrovascular pathology compared to other state-of-the-art techniques.[15] It is only with accurate hippocampal segmentation in difficult cases with extensive pathology that hippocampal shape analysis can be reliably performed. Third, our unique approach of hippocampal shape analysis and regional WMH distribution revealed novel spatial vulnerabilities of these co-occurring disease processes in the hippocampus not captured by global volume measurements used in previous studies.

This study has several limitations. First, we did not validate our findings in an independent cohort. To our knowledge, an independent cohort with moderate–high WMH load and amyloid PET imaging does not currently exist, underscoring the value of the MITNEC-C6 trial and importance of studying the mixed dementia phenotype in future studies. Second, the study is cross-sectional by design. Future work with longitudinal analyses will serve to evaluate the directionality and dynamic interplay between these co-pathologies on hippocampal degeneration. Third, the impact of other neuroimaging biomarkers of SVD on hippocampal integrity, including MRI-visible PVS, lacunes, and microbleeds, were not examined. The topographical distributions of SVD imaging markers may represent different underlying vasculopathies.[3,13,14,23–26] Thus, characterizing their relative contributions to the spatial pattern of hippocampal degeneration may serve to further clarify underlying heterogeneity in brain atrophy and clinical trajectories within individual patients with mixed pathologies. Finally, we did not validate these results in an independent dataset with low SVD burden (i.e., total WMH volume < 6 cm³ or 0.65% of total intracranial volume, Fazekas score < 2) or cognitively unimpaired older individuals. Some studies report reduced hippocampal volume associated with low WMH burden in cognitively normal, MCI, or AD individuals in the absence of Aβ pathology.[4,9] Other studies support a threshold beyond which vascular pathology drives hippocampal degeneration.[8,20–22] To assess the generalizability of our findings, cohorts with lower burden of white matter injury and concurrent Aβ positivity will be needed. Localized hippocampal degeneration linked to dementia is visible on structural MRI even in cognitively normal older adults,[12,20–22] which highlights the potential of hippocampal shape analysis for detecting regional susceptibilities to AD and SVD pathology at earlier stages of disease.

Machine and deep learning classification algorithms offer a powerful approach to translate these research findings into clinical practice. Future work should use hippocampal shape analysis for extracting relevant features (i.e., global and/or spatially localized

morphometric parameters) to predict amyloid status and SVD burden on an individualized basis. We expect the distinct pattern of regional hippocampal shape alterations associated with Aβ and white matter injury detected in the present study to be recapitulated as important predictive features for patient classification. The ability to distinguish the relative contributions of vascular and Aβ-related processes to neurodegeneration paves the way toward precision medicine in mixed dementia, informing both clinical diagnosis and disease-specific therapeutic strategies. A shape-based classification approach would require training and validation in a larger cohort of participants than the current study and across multiple cohorts to ensure robustness and generalizability.

In conclusion, these findings suggest that SVD, both independently and via Aβ-related pathways, drives hippocampal degeneration through regionally specific pathways in the early stages of cognitive impairment. Our results support the use of hippocampal morphometry as a sensitive biomarker that can reveal deeper insight into the overlapping pathogenic mechanisms of SVD and AD, capture the relative impact of AD and SVD pathologies on neurodegeneration in a personalized medicine approach, and inform the design of disease-modifying therapeutic trials with hippocampal degeneration as an outcome measure.

CONFLICT OF INTEREST STATEMENT

S.E.B. reports contracted research from the following, with no personal investigator fees taken: GE Healthcare, Genentech, Optina, Roche, Eli Lilly, Eisai, Biogen Idec, NovoNordisk, Lilly Avid, UCB Biopharma SRL, Merck, Alkahest Inc.; consulting fees from Roche, Biogen, and NovoNordisk; and honoraria for lectures from Biogen. M.B. reports contractual funds paid to the Lawson Health Research Institute from Biogen, Alector, Eisai, Abbvie, and Eli Lilly; consulting fees for the co-creation of workshops from Roche; and honoraria for educational webinars and educational website modules from Biogen. H.C. reports pharmaceutical trial contracts sponsored by Hoffmann-La Roche Limited, TauRx, Lilly, Anavex Life Sciences, Alector LLC, Biogen, and Immunocal; participation as an unpaid advisor in 2020 for the establishment of an international database by Biogen; and is the scientific director of CCNA, which is partnered with Pfizer Inc., Lilly, and Sanofi. P.H.K. reports payments made to the institution for research from Blue Earth Diagnostics, GE Healthcare, and Novartis; consulting fees

from Amgen, Bayer, Blue Earth Diagnostics, Chimerix, Eisai, Fusion Pharma, GE Healthcare, Invicro, Novartis, and Radionetics; honoraria for lectures from Urology Today, GE Healthcare, and Invicro; US patent for brain imaging (Patent No. US 10,013,743 B2); payments from Amgen, GE Healthcare, and Radionetics for data safety monitoring or advisory board; and medical writing for Novartis, GE Healthcare, and Blue Earth Diagnostics. J.C.T. reports grants or contracts from Amarin, AstraZeneca, Ceapro, DalCor Pharmaceuticals, Esperion, Ionis, Merck, Novartis, Pfizer, and RegenXBio; consulting fees from AstraZeneca, DalCor Pharmaceuticals, and HLS Pharmaceuticals; honoraria from HLS Pharmaceuticals, Pendopharm, Pfizer; and patents planned or pending from Pharmacogenomics-guided CETP inhibition use of colchicine after myocardial infarction; and stock options of minor equity interest in DalCor Pharmaceuticals. A.T. reports a research contract with Bayer Inc. K.Z. reports grants/contracts from Microsoft Canada; consulting fees from Fusion Pharmaceuticals, Invicro, and GE Healthcare. K.X., J.O., E.G., C.S., G.J.F., S.A., R.F., R.J.L., M.D.N., F.S.P., D.J.S., E.E.S., V.S., J.P.S., M.G., and J.R. have no conflicts of interest to disclose. Author disclosures are available in the supporting information.

CONSENT STATEMENT

All MITNEC-C6 participants provided written informed consent. Research was ethically conducted and approved by each participating institutional ethics board.

ORCID

Kristiana Xhima https://orcid.org/0000-0003-4071-8319
Joel Ramirez https://orcid.org/0000-0002-5582-1776

REFERENCES

1. Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. *Acta Neuropathol.* 2017;134(2):171-186. doi:10.1007/s00401-017-1717-7
2. Jack CR, Bennett DA, Blennow K, et al. NIA-AA Research Framework: toward a biological definition of Alzheimer's disease. *Alzheimers Dement.* 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018
3. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* 2013;12(8):822-838. doi:10.1016/S1474-4422(13)70124-8
4. Fiford CM, Manning EN, Bartlett JW, et al. White matter hyperintensities are associated with disproportionate progressive hippocampal atrophy. *Hippocampus.* 2017;27(3):249-262. doi:10.1002/hipo.22690
5. Vipin A, Foo HJL, Lim JKW, et al. Regional white matter hyperintensity influences grey matter atrophy in mild cognitive impairment. *J Alzheimers Dis.* 2018;66(2):533-549. doi:10.3233/JAD-180280
6. Rizvi B, Sathishkumar M, Kim S, et al. Posterior white matter hyperintensities are associated with reduced medial temporal lobe subregional integrity and long-term memory in older adults. *Neuroimage Clin.* 2023;37:103308. doi:10.1016/j.nicl.2022.103308
7. Wong FCC, Yatawara C, Low A, et al. Cerebral small vessel disease influences hippocampal subfield atrophy in mild cognitive impairment. *Transl Stroke Res.* 2021;12(2):284-292. doi:10.1007/s12975-020-00847-4
8. Freeze WM, Jacobs HI, Gronenschild EH, et al. White matter hyperintensities potentiate hippocampal volume reduction in

non-demented older individuals with abnormal amyloid-β. *J Alzheimers Dis.* 2017;55(1):333-342. doi:10.3233/JAD-160474

9. Ye BS, Seo SW, Kim GH, et al. Amyloid burden, cerebrovascular disease, brain atrophy, and cognition in cognitively impaired patients. *Alzheimers Dement.* 2015;11(5):494-503. doi:10.1016/j.jalz.2014.04.521

10. McNeely AA, Ramirez J, Nestor SM, et al. Cholinergic subcortical hyperintensities in Alzheimer's disease patients from the Sunnybrook Dementia Study: relationships with cognitive dysfunction and hippocampal atrophy. *J Alzheimers Dis.* 2015;43(3):785-796. doi:10.3233/JAD-140588

11. Nestor SM, Mišić B, Ramirez J, et al. Small vessel disease is linked to disrupted structural network covariance in Alzheimer's disease. *Alzheimers Dement.* 2017;13(7):749-760. doi:10.1016/j.jalz.2016.12.007

12. Van Etten EJ, Bharadwaj PK, Hishaw GA. Influence of regional white matter hyperintensity volume and apolipoprotein E ε4 status on hippocampal volume in healthy older adults. *Hippocampus.* 2021;31(5):469-480. doi:10.1002/hipo.23308

13. Brickman AM, Rizvi B. White matter hyperintensities and Alzheimer's disease: an alternative view of an alternative hypothesis. *Alzheimers Dement.* 2023;19(9):4260-4261. doi:10.1002/alz.13371

14. Garnier-Crussard A, Bougacha S, Wirth M, et al. White matter hyperintensity topography in Alzheimer's disease and links to cognition. *Alzheimers Dement.* 2022;18(3):422-433. doi:10.1002/alz.12410

15. Goubran M, Ntiri EE, Akhavein H, et al. Hippocampal segmentation for brains with extensive atrophy using three-dimensional convolutional neural networks. *Hum Brain Mapp.* 2020;41(2):291-308. doi:10.1002/hbm.24811

16. Styner M, Oguz I, Xu S, et al. Framework for the statistical shape analysis of brain structures using SPHARM-PDM. *Insight J.* 2006(1071):242-250.

17. Ottoy J, Ozzoude M, Zukotynski K, et al. Vascular burden and cognition: mediating roles of neurodegeneration and amyloid PET. *Alzheimers Dement.* 2023;19(4):1503-1517. doi:10.1002/alz.12750

18. Gibson E, Gao F, Black SE, Lobaugh NJ. Automatic segmentation of white matter hyperintensities in the elderly using FLAIR images at 3T. *J Magn Reson Imaging.* 2010;31(6):1311-1322. doi:10.1002/jmri.22004

19. Ramirez J, Gibson E, Quddus A, et al. Lesion Explorer: a comprehensive segmentation and parcellation package to obtain regional volumetrics for subcortical hyperintensities and intracranial tissue. *Neuroimage.* 2011;54(2):963-973. doi:10.1016/j.neuroimage.2010.09.013

20. Wu M, Schweitzer N, Iordanova BE, et al. Pre-clinical AD small vessel disease is associated with altered hippocampal connectivity and atrophy. *Am J Geriatr Psychiatry.* 2023;31(2):112-123. doi:10.1016/j.jagp.2022.09.011

21. van Leijsen EMC, Tay J, van Uden IWM, et al. Memory decline in elderly with cerebral small vessel disease explained by temporal interactions between white matter hyperintensities and hippocampal atrophy. *Hippocampus.* 2019;29(6):500-510. doi:10.1002/hipo.23039

22. van Uden IW, van der Holst HM, Tuladhar AM, et al. White matter and hippocampal volume predict the risk of dementia in patients with cerebral small vessel disease: the RUN DMC study. *J Alzheimers Dis.* 2016;49(3):863-873. doi:10.3233/JAD-150573

23. Weaver NA, Doeven T, Barkhof F, et al. Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. *Neurobiol Aging.* 2019;84:225-234. doi:10.1016/j.neurobiolaging.2019.08.001

24. Lee S, Viqar F, Zimmerman ME, et al. White matter hyperintensities are a core feature of Alzheimer's disease: evidence from the dominantly inherited Alzheimer network. *Ann Neurol.* 2016;79(6):929-939. doi:10.1002/ana.24647

25. Fotiadis P, van Rooden S, van der Grond J, et al. Cortical atrophy in patients with cerebral amyloid angiopathy: a case-control study. *Lancet Neurol.* 2016;15(8):811-819. doi:10.1016/S1474-4422(16)30030-8

26. Thanprasertsuk S, Martinez-Ramirez S, Pontes-Neto OM, et al. Posterior white matter disease distribution as a predictor of amyloid angiopathy. *Neurology.* 2014;83(9):794-800. doi:10.1212/WNL.0000000000000732

27. Lahna D, Schwartz DL, Woltjer R, et al. Venous collagenosis as pathogenesis of white matter hyperintensity. *Ann Neurol.* 2022;92(6):992-1000. doi:10.1002/ana.26487

28. Keith J, Gao F, Noor R, et al. Collagenosis of the deep medullary veins: an underrecognized pathologic correlate of white matter hyperintensities and periventricular infarction? *J Neuropathol Exp Neurol.* 2017;76(4):299-312. doi:10.1093/jnen/nlx009

29. Makedonov I, Black SE, MacIntosh BJ. Cerebral small vessel disease in aging and Alzheimer's disease: a comparative study using MRI and SPECT. *Eur J Neurol.* 2013;20(2):243-250. doi:10.1111/j.1468-1331.2012.03785.x

30. Haight TJ, Landau SM, Carmichael O, et al. Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism. *JAMA Neurol.* 2013;70(8):1039-1045. doi:10.1001/jamaneurol.2013.1878

31. Cabinio M, Saresella M, Piancone F, et al. Association between hippocampal shape, neuroinflammation, and cognitive decline in Alzheimer's disease. *J Alzheimers Dis.* 2018;66(3):1131-1144. doi:10.3233/JAD-180250

32. Femminella GD, Dani M, Wood M, et al. Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. *Neurology.* 2019;92(12):e1331-e1343. doi:10.1212/WNL.0000000000007133

SUPPORTING INFORMATION

Additional supporting information can be found online in the Supporting Information section at the end of this article.